Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.
Full description
Melanoma is a heterogeneous skin tumor, characterized by mutations of different oncogenes. Almost half of patients with advanced melanoma have a gene mutation of BRAF serine-threonine kinase. Over the past 5 years, two BRAF inhibitors targeting these mutations, vemurafenib and dabrafenib, have shown high rates of rapid response in phase II and III studies. However, the duration of responses is limited in most patients due to the development of acquired resistance. Mechanisms of resistance to BRAF inhibitor therapy are diverse and include the reactivation of the mitogen-activated protein kinase (MAPK) pathway in over two-thirds of tumors, along with promotion of parallel signaling networks.
Recently, the combination of drugs was superior in terms of responses, Progression Free Survival (PFS) and Overall Survival (OS) compared to monotherapy.
The data from recent studies confirm the clinical benefit of the combination of Vemurafenib with cobimetinib and support the use of the combination as a standard first-line approach to improve survival in patients.
The aim of this randomized, open-label, phase II study is to evaluate the efficacy, in terms of overall survival, of vemurafenib combined with cobimetinib associated with local treatment compared with second-line therapy, in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with histologically confirmed melanoma, either unresectable Stage IIIc or Stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition
Patients previously untreated for metastatic melanoma
Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples) by a validated mutational test
Adequate performance status to receive vemurafenib and cobimetinib therapy as determined by treating physician
Male or female patient aged ≥18 years
Able to participate and willing to give written informed consent prior to any treatment-related procedures and to comply with treatment guidance
Adequate end-organ function, defined by the following laboratory results obtained within 14 days prior to the first dose of program drug treatment:
Bilirubin ≤ 1.5 x the upper limit of normal (ULN).
AST, ALT, and alkaline phosphatase ≤ 3 x ULN, with the following exceptions:
Serum creatinine ≤1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min based on measured CrCl from a 24-hour urine collection or Cockroft-Gault glomerular filtration rate estimation.
Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two effective forms of contraception during program therapy and for at least 6 months after completion of program therapy
Negative serum pregnancy test prior to commencement of dosing in women of childbearing potential
Patient should be able to swallow tablets
Absence of any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the treatment regimen
Patient does not currently participate in other clinical trials
Exclusion criteria
Palliative radiotherapy within 7 days prior to the first dose of program treatment
Patients with active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years except for patients with resected melanoma, resected BCC, resected cutaneous SCC, resected melanoma in situ, resected carcinoma in situ of the cervix, and resected carcinoma in situ of the breast
Evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment / central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration
Systemic risk factor for RVO including uncontrolled glaucoma, uncontrolled hypercholesterolemia, hypertriglyceridemia or hyperglycemia
History of clinically significant cardiac dysfunction, including the following:
Current severe, uncontrolled systemic disease
Major surgery or traumatic injury within 14 days prior to first dose of program treatment
History of malabsorption or other condition that would interfere with absorption of program drugs
Hypersensitivity to the active substance or to any of the excipients
Pregnant or breastfeeding women
Primary purpose
Allocation
Interventional model
Masking
120 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal